AmbioPharm Inc is a peptide CDMO based in North Augusta, SC, with major operations in Shanghai. Here's who owns it, what it makes, and what buyers should know.
AmbioPharm Inc is a peptide-focused contract development and manufacturing organization (CDMO) headquartered in North Augusta, South Carolina, with major manufacturing operations in Shanghai, China. The company synthesizes peptides for pharmaceutical and biotech clients instead of selling peptides directly to consumers. The Carlyle Group holds a controlling investment in the business.
What Does AmbioPharm Inc Do?
AmbioPharm is a CDMO, which means it manufactures peptides on behalf of other companies rather than selling them under its own label. Clients hire the company to develop a synthetic route, scale it up, and produce clinical and commercial batches under formal quality systems.
Core services include:
- Solid-phase and hybrid peptide synthesis, from grams to multi-kilogram commercial batches
- Process development and scale-up for long-chain and complex peptides
- Purification and analytical testing, including HPLC and mass spectrometry
- Regulatory documentation support for FDA and EMA filings
- Lyophilization and fill-finish support for peptide APIs
Because the business is strictly business-to-business, ambiopharm peptides are supplied to drug developers, biotechs, and other manufacturers that need extra capacity — not to individual buyers.
Where Is AmbioPharm Located?
AmbioPharm runs a two-continent manufacturing footprint. The ambiopharm locations most often cited are the US headquarters and the Chinese peptide plant, which together give the company both domestic and cost-competitive production capacity.
- North Augusta, South Carolina — corporate headquarters and US peptide manufacturing site.
- Shanghai, China — large-scale peptide API manufacturing, frequently searched as Shanghai AmbioPharm Inc.
A US site matters for clients who need a domestic supply chain, while the Shanghai operation supports higher-volume and cost-sensitive programs. That dual footprint is a key part of how the company positions itself against European competitors.
Who Owns AmbioPharm? The Carlyle Connection
AmbioPharm is private-equity backed, and The Carlyle Group holds a controlling investment in the company. That ownership is the main reason searches for "AmbioPharm Carlyle" and "who owns AmbioPharm" surface so often.
Private equity ownership usually means capital for capacity expansion, equipment, and hiring. It also means the ownership picture can shift through a future sale or recapitalization, so anyone tracking the company should follow corporate announcements rather than assume today's structure is permanent.
What Peptides Does AmbioPharm Make?
AmbioPharm manufactures a broad range of synthetic peptides, including generic and innovator molecules used in metabolic disease, oncology, and rare disease programs. GLP-1 peptides are the single biggest growth driver in the peptide CDMO market right now.
The GLP-1 and Tirzepatide Angle
Demand for ambiopharm tirzepatide and semaglutide manufacturing has risen sharply as obesity and diabetes treatments have scaled up worldwide. In practice, that means the company produces tirzepatide as an active pharmaceutical ingredient for its clients — it is not a consumer product sold under the AmbioPharm name. Peptide CDMOs able to run large GLP-1 campaigns at commercial scale are in short supply.
Can You Buy AmbioPharm Peptides Online?
No. Websites advertising peptides under the AmbioPharm name are almost always unaffiliated research chemical sellers borrowing a manufacturer's reputation for credibility. AmbioPharm does not operate a consumer storefront, and its products leave the facility only under contract with pharmaceutical clients.
That distinction matters for safety. Peptides sold as "research chemicals" online are not FDA-approved for human use, are frequently unverified for identity and purity, and carry real risks when injected. Anyone considering a peptide for a health condition should talk with a licensed healthcare professional instead of buying from an anonymous vendor.
AmbioPharm Jobs, Employees, and Salary Expectations
Staff work across peptide chemistry, analytical development, quality control, manufacturing operations, supply chain, and corporate functions at the US and China sites. Total headcount sits in the several-hundred range and tends to grow whenever manufacturing capacity expands.
Typical ambiopharm jobs include:
- Research associate and scientist roles in peptide synthesis and process development
- Quality control analyst, quality assurance specialist, and validation engineer positions
- Manufacturing technician and production supervisor roles
- Regulatory affairs, project management, and business development
Pay follows the broader CDMO market. Entry-level lab technicians often start in the $45,000–$65,000 range in South Carolina, experienced scientists and engineers commonly land between $75,000 and $130,000, and senior leadership roles run higher. Compensation in Shanghai follows local market rates and is not directly comparable to US figures.
How AmbioPharm Compares With Other Peptide CDMOs
| Company | Base | Peptide focus | Notes for buyers |
|---|---|---|---|
| AmbioPharm Inc | US and China | Synthetic peptides, GLP-1 APIs, generic peptides | US + China capacity; Carlyle-backed |
| Bachem | Switzerland | Peptides and oligopeptides | Among the largest dedicated peptide CDMOs |
| PolyPeptide Group | Europe and US | Peptide APIs | Multiple global manufacturing sites |
| CordenPharma | Europe, US, Asia | Peptides, lipids, injectables | Broad CDMO portfolio beyond peptides |
Buyers comparing peptide capacity often evaluate CordenPharma AmbioPharm side by side, since both serve large pharmaceutical clients and compete for GLP-1 and generic peptide programs. The right partner depends on batch size, regulatory requirements, timeline, and whether a domestic supply chain is mandatory.
Key Takeaways About AmbioPharm Inc
- AmbioPharm Inc is a peptide CDMO, not a drug developer or a retail peptide seller.
- The company operates manufacturing sites in North Augusta, South Carolina, and Shanghai, China.
- The Carlyle Group holds a controlling investment in AmbioPharm.
- AmbioPharm produces peptides such as tirzepatide and semaglutide for pharmaceutical clients.
- Websites claiming to sell AmbioPharm products directly to consumers are not affiliated with the company.
Frequently Asked Questions
Who owns AmbioPharm Inc?
AmbioPharm Inc is backed by The Carlyle Group, which holds a controlling investment in the company. Because it is privately held, ownership details come from corporate announcements rather than public filings. That structure could change if the company is sold or recapitalized in the future.
Does AmbioPharm sell peptides to individual buyers?
No. AmbioPharm is a business-to-business contract manufacturer, so it supplies peptides to pharmaceutical and biotech clients under contract rather than selling to consumers. Websites offering peptides under the AmbioPharm name are generally unaffiliated third parties. Peptides sold as research chemicals are not FDA-approved for human use.
Where is AmbioPharm located?
AmbioPharm's corporate headquarters and US peptide manufacturing site are in North Augusta, South Carolina. The company also operates a large peptide API facility in Shanghai, China, which supports higher-volume production. This two-continent footprint lets clients choose between domestic and cost-sensitive manufacturing options.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.